DCTH

In September 2026, Delcath announced inducement grants, leading to a 3.33% stock price increase seven days prior to September 18. In August 2026, the company reported strong second-quarter results and business highlights, causing a 22.49% stock increase on August 6, and raised its full-year 2026 revenue guidance to $104 million to $108 million, projecting at least 28% growth in HEPZATO KIT volume. Delcath also updated its corporate bylaws and governance framework on August 14, 2026. In July 2026, the company participated in the Canaccord Genuity 46th Annual Growth Conference, hosted its second-quarter earnings call, and announced the first patient dosed in a Phase 2 clinical trial of HEPZATO™ for liver-dominant metastatic breast cancer in Milan, Italy. In May 2026, Delcath Systems held its first-quarter 2026 earnings call. As of September 15, 2026, the share price was $16.17, marking a 46.73% increase over the past year, with a 61.96% increase over the last 12 months and a year-to-date return of 66.93% as of August 21, 2026.